WO2017143361A1 - Treatment for spirochete borne illness - Google Patents
Treatment for spirochete borne illness Download PDFInfo
- Publication number
- WO2017143361A1 WO2017143361A1 PCT/US2017/028452 US2017028452W WO2017143361A1 WO 2017143361 A1 WO2017143361 A1 WO 2017143361A1 US 2017028452 W US2017028452 W US 2017028452W WO 2017143361 A1 WO2017143361 A1 WO 2017143361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- administering
- biofilm
- patient
- minocycline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to a combination of two or more short and long acting anti- pathogenic compounds, including tinidazole, and Artemisia derivatives, which dissolve the protective biofilm barriers of microbes found within the blood vessel walls or any nearby tissue to treat Borellia, Babesia, and other biofilm producing pathogens and amoebas.
- Borrelia is called the great imitator because it can imitate (cause) any disease anywhere in the body.
- many diseases such as Diabetes, MS, ALS, Lupus, Rheumatoid Arthritis, Ehler's-Danlos type 3, Fibromyalgia, Alzheimer's, Dementia, Parkinson's, Autism, etc. are probably caused by Borrelia.
- the CDC is currently unable to detect Borrelia in late stage (chronic) Lyme and therefore attributes the symptoms to psychiatric diseases or rheumatoid arthritis.
- late stage Lyme can be cured with the antibiotic regimen described within.
- Biofilms are any group of microorganisms in which cells stick to each other on a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). Biofilms are the predominant mode of growth of bacteria in the natural environment, and bacteria growing in biofilms exhibit distinct physiological properties.
- EPS extracellular polymeric substance
- the bacteria in a biofilm are more resistant to antibiotics, UV irradiation, detergents and the host immune response (Gristina et al. 1988. Journal of the American Medical Association, 259: 870-874; Stewart. 1994. Antimicrobial Agents & Chemotherapy, 38(5): 1052-1058; Costerton et al. 1995. Annu. Rev. Microbiol., 49: 71 1-745; Maira Litran et al. 2000. Journal of Applied Microbiology, 88: 243-247).
- a biofilm may include one or more microorganisms, including gram-positive and gram-negative bacteria, algae, protozoa, and/or yeast or filamentous fungi and viruses and/or bacteriophage.
- microorganisms including gram-positive and gram-negative bacteria, algae, protozoa, and/or yeast or filamentous fungi and viruses and/or bacteriophage.
- problematic biofilms are dental plaque, infections on medical implants, but also the initial fouling on ship hulls (Satuito et al. 1997. Hydrobiologia, 358: 275-280).
- Biofilms are attributed to the pathogenesis of many infections in humans. New strategies are required to disperse existing biofilm.
- biofilms can have, as a component, DNA (termed extracellular DNA or eDNA) although its function there remains unknown. Certain groups have sought to employ nuclease enzymes to disrupt biofilms.
- Borrelia like the other microbes produces biofilm and has active spirochete forms. Also, Borrelia has cysts which are spirochetes balled up and encapsulated in biofilm. The spirochete form of Borrelia is very mobile and can penetrate deep into any body tissues including cartilage, tendons, and bones.
- Tinidazole is the best molecule currently known for dissolving biofilms.
- Metronidazole Fluorine-based Fluoride
- Flagyl is in the same drug class as tinidazole and can work in a similar fashion, however Flagyl is not as effective as Tindamax for dissolving biofilms and Flagyl has more adverse side effects.
- Other compounds such as nattokinase and serrapeptase can dissolve biofilms, however they are not very effective in a patient treatment setting even though nattokinase and serrapeptase are less expensive than Tindamax.
- Tindamax eliminates biofilm from the body because atmospheric biofilm disruption does not reduce the total volume of biofilm in one's body, but rather, it breaks apart larger chunks of biofilm into smaller chunks.
- Anti-microbials are used concurrently with biofilm disruption techniques to kill the microbes that are released when biofilm is broken apart or destroyed because when biofilm is dissolved, pathogenic organisms are usually released into the body or bloodstream. Otherwise, if biofilm is broken up too rapidly, several things can happen. First, pathogens may be released into the bloodstream so quickly that sepsis ensues which can be harmful (life-threatening) to the patient. Second, rapid physical 'chopping' of large biofilm chunks can break them apart into smaller chunks which can then block blood vessels causing a whole bunch of problems such as heart attack, stroke, TIA, seizure, organ damage/failure due to lack of blood flow, etc.
- Tinidazole is only good at destroying biofilm and it is very limited in killing actual organisms.
- This invention uses a minimum of two or three antibiotics for the treatment of Borrellia.
- One antibiotic is required to dissolve Borrelia biofilm.
- a second or third antibiotic is required to kill the active spirochetes.
- the current invention uses the brand name Tindamax (tinidazole), marketed by Mission Pharmacal, or Fasigyn and Simplotan marketed by Pfizer, which attacks the biofilm that the bacteria use to protect themselves, rendering most drug treatments useless.
- Tinidazole' s The chemical name for Tinidazole' s is C 8 H 13 N 3 O 4 S.
- the biofilm stops the drugs from reaching the bacteria, and this prevents their treatment regardless of which drugs are used.
- Tinidazole should be used to dissolve biofilms.
- Other nitroimidazole class drugs may be used instead of tinidazole to dissolve biofilm.
- Minocycline is the best Borrelia antibiotic because it is lipophilic and penetrates most, if not all, body tissues including the central nervous system. Doxycycline may also be used, but doxycycline does not work as well because it does not penetrate all body tissues.
- Vitamin D3 (cholecalciferol) is Borrelia's most usable form of food. Vitamin D3 is also lipophilic with a half-life of one to two weeks. Vitamin D3 may be co-administered with minocycline to enhance the uptake of minocycline, which enhances the efficacy of minocycline.
- Minocycline's half-life is about 12-14 hours.
- a fluoroquinolone such as Levaquin is also recommended for co-administration.
- Levaquin is both water and lipid soluble and penetrates many body tissues pretty well.
- Other fluoroquinolones such as ciprofloxacin may be used, but do not work as well as Levaquin.
- a penicillin class drug such as amoxicillin or bicillin may be used to substitute a tetracycline class drug due to bone (teeth) staining.
- teeth bone staining
- Sulfa class drugs such as Septra DS may be used, but usually with limited success and a high resistance rate.
- This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim.
- Palliative support such as pain meds, glutathione, and rest may be necessary to accommodate herxing because with other Lyme co-infections, herxing can be severe.
- the invention provides a pharmaceutical composition for disrupting a biofilm or preventing biofilm formation comprising a Tinidazole drug combination.
- compositions described herein can be formulated for oral administration.
- composition in any of the pharmaceutical compositions described herein can be formulated as a liquid, lotion, cream, spray, gel, ointment, or powder, and the like.
- compositions describe herein can be formulated for use in the treatment of a wide range of medical indications.
- composition is a pharmaceutical composition
- said composition can be for administration to an animal patient.
- the animal patient can be a mammalian patient.
- the mammalian patient can be a human.
- the invention also provides a method of disrupting a biofilm on a patient comprising contacting a biofilm on a patient with any of the pharmaceutical compositions described herein.
- the patient can be an animal patient.
- the patient can be a mammalian patient.
- the patient can be a human.
- the biofilm can comprise gram-positive bacteria.
- formulations include topical lotions, creams, soaps, wipes, and the like. They may be formulated into liposomes, to reduce toxicity or increase bioavailability.
- Other methods for delivery include oral methods that entail encapsulation of the polypeptide or peptide in microspheres or proteinoids, aerosol delivery (e.g., to the lungs), or transdermal delivery (e.g., by iontophoresis or transdermal electroporation). Other routine methods of administration will be known to those skilled in the art.
- compositions described herein suitable for oral administration may be provided in convenient unit forms including capsules, tablets, gels, pastes, ointments etc.
- Preparations for parenteral administration of pharmaceutical formulations comprising compositions described herein include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters such as ethyl oleate.
- aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions.
- parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer' s, and fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives such as, other antimicrobial, antioxidants, chelating agents, inert gases and the like also can be included.
- any of the pharmaceutical compositions may be formulated as an ointment, cream, or lotion.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, suspending agents, thickening agents, or coloring agents.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662296681P | 2016-02-18 | 2016-02-18 | |
US62/296,681 | 2016-02-18 | ||
US15/436,853 US20180235982A1 (en) | 2017-02-19 | 2017-02-19 | Treatment for Spirochete borne illness |
US15/436,853 | 2017-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017143361A1 true WO2017143361A1 (en) | 2017-08-24 |
Family
ID=59626254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/028452 WO2017143361A1 (en) | 2016-02-18 | 2017-04-19 | Treatment for spirochete borne illness |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017143361A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093876A2 (en) * | 2003-04-03 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois | Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders |
US20160002277A1 (en) * | 2013-03-12 | 2016-01-07 | Laszlo Sichtnik | Compositions and methods for treating infectious disease |
US20160045520A1 (en) * | 2014-08-18 | 2016-02-18 | Fabrizio De Silvestri | Use in one pill tablet capsule minocycline acycloguanosine atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis |
-
2017
- 2017-04-19 WO PCT/US2017/028452 patent/WO2017143361A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093876A2 (en) * | 2003-04-03 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois | Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders |
US20160002277A1 (en) * | 2013-03-12 | 2016-01-07 | Laszlo Sichtnik | Compositions and methods for treating infectious disease |
US20160045520A1 (en) * | 2014-08-18 | 2016-02-18 | Fabrizio De Silvestri | Use in one pill tablet capsule minocycline acycloguanosine atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis |
Non-Patent Citations (1)
Title |
---|
NICOLSON: "Diagnosis and Therapy of Chronic Systemic Co-Infections in Lyme Disease and Other Tick-Borne Infectious Diseases, Lyme Disease Diagnosis & Therapy Suggestions", ACAM MEETING, 2006, XP055410966, Retrieved from the Internet <URL:http://www.immed.org/treatment%20considerations/NicolsonLYMEdiseaseACAM_06.rtf> [retrieved on 20170613] * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2756773C2 (en) | Compositions based on cannabidiol and their use methods | |
CA2842777C (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
US20150264935A1 (en) | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same | |
Lang et al. | Tyrothricin–an underrated agent for the treatment of bacterial skin infections and superficial wounds? | |
EP3681468B1 (en) | Antimicrobial composition | |
EP1773313A2 (en) | Control of biofilm formation | |
CN1230117A (en) | Pharmaceutical compsns. with antimicrobial activity | |
JP6783476B2 (en) | Antibacterial composition containing mupirocin and neomycin | |
US20060264411A1 (en) | Control of biofilm formation | |
CN102363040B (en) | Antimicrobial peptide preparation for mucosal tissues | |
EP3210619A2 (en) | Topical formulation for treating skin or mucosal infections, preparation method and uses thereof | |
WO2017143361A1 (en) | Treatment for spirochete borne illness | |
CN107921102A (en) | Combination treatment | |
US20180235982A1 (en) | Treatment for Spirochete borne illness | |
TW201924672A (en) | Antibacterial treatment using cannabinoids | |
EP4054525B1 (en) | Provision of bacteriophages in various dosage forms and bacteriophage application device | |
RU2613708C2 (en) | Ways of acne treatment | |
US6998109B1 (en) | Emu-based formulations with lidocaine for wound treatment by inhibiting microbial activity | |
US7476379B1 (en) | Emu-based formulations for the treatment of damaged skin by inhibiting microbial and fungal activity | |
WO2017143360A1 (en) | Treatment for microbial borne illness | |
US20180235977A1 (en) | Treatment for Microbial borne illness | |
WO2017143362A1 (en) | Treatment for protozoa borne illness | |
RU2781050C1 (en) | Bactericidal pharmaceutical composition for topical application in the form of an endolysin-containing bactericidal gel | |
CN102125562A (en) | Medicinal composition for injection for treating superbug | |
US20150224177A1 (en) | Methods for therapeutic or prophylactic treatment of melioidosis and/or associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17754055 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17754055 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 07.03.2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17754055 Country of ref document: EP Kind code of ref document: A1 |